非酒精性脂肪肝潜在药物研究进展

发布时间：2018-04-23 18:34

本文选题：非酒精性脂肪肝病 + 法尼酯X受体　；参考：《中国新药杂志》2017年14期

【摘要】：非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是21世纪世界范围的重要的公共健康问题,在中国也越来越得到重视。其发病过程与胰岛素抵抗、肥胖、2型糖尿病及高脂血症密切相关,由于复杂的发病机制,市场上并没有针对NAFLD的特效药。目前,一些相应的治疗药物包括胰岛素增敏剂类、降脂类、抗氧化应激类及保肝类药物等等,也均未能完全逆转NAFLD的发展。治疗NAFLD一线用药的空缺促使研究者进行新颖治疗方法的开发。因此,本文将对各通路的治疗靶点及相关药物的临床研究进行回顾总结,对NAFLD的治疗进行较详细的综述,以期对研究有效改善NAFLD的药物提供一些思路。
[Abstract]:Non-alcoholic fatty liver disease (NAFLD) is an important public health problem worldwide in the twenty-first Century. It is also becoming more and more important in China. Its pathogenesis is closely related to insulin resistance, obesity, type 2 diabetes and hyperlipidemia. It is caused by complex pathogenesis and is not targeted at NAFLD in the market. At present, some corresponding therapeutic drugs, including insulin sensitizer, lipid lowering, antioxidant stress and liver preservation drugs, have not completely reversed the development of NAFLD. The treatment of NAFLD front-line medication has prompted the researchers to develop new treatment methods. Therefore, this article will target the treatment of various pathways and the correlation. The clinical research of drugs is reviewed and summarized, and the treatment of NAFLD is reviewed in detail, so as to provide some ideas for studying the drugs that can effectively improve NAFLD.

【作者单位】：天津大学药物科学与技术学院;天士力研究院药理毒理研究中心;
【分类号】：R575.5

【参考文献】